Paper32014348
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.
Shah R and 1 other. Clin Lung Cancer, 2020. Cited by 144 papers, by iCite.
Cite this record
ConductScience Library. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. Papers, record 32014348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32014348
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Mutation | Major topic |
| Protein Kinase Inhibitors | Major topic |
| ErbB Receptors | |
| Humans |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04970693 | A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | Background |
Source ClinicalTrials.gov
Cited by89
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 144 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42728535 | Osimertinib Plus Platinum-Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC. | Target Oncol | 2026 | https://conductscience.org/library/papers/42728535 | PubMed |
| 42390540 | Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome. | Cancer Chemother Pharmacol | 2026 | https://conductscience.org/library/papers/42390540 | PubMed |
| 42346070 | MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. | Cells | 2026 | https://conductscience.org/library/papers/42346070 | PubMed |
| 42243148 | The cumulative impact of passenger mutations on cancer development. | Nat Commun | 2026 | https://conductscience.org/library/papers/42243148 | PubMed |
| 41851431 | Inhalable Therapeutics in Lung Cancer: Overcoming Barriers for Effective Treatment. | AAPS PharmSciTech | 2026 | https://conductscience.org/library/papers/41851431 | PubMed |
| 41836111 | The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand? | Int J Gen Med | 2026 | https://conductscience.org/library/papers/41836111 | PubMed |
| 41821616 | Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41821616 | PubMed |
| 41759225 | ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors. | ESMO Open | 2026 | https://conductscience.org/library/papers/41759225 | PubMed |
| 41683957 | SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41683957 | PubMed |
| 41512055 | 3D organotypic skin models recapitulate autoantibody-driven pemphigus pathomechanisms and targeted therapeutic response. | Sci Adv | 2026 | https://conductscience.org/library/papers/41512055 | PubMed |
| 41159074 | Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy - a literature review. | RSC Adv | 2025 | https://conductscience.org/library/papers/41159074 | PubMed |
| 41143954 | EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41143954 | PubMed |
| 40872484 | Predicting EGFRL858R/T790M/C797S Inhibitory Effect of Osimertinib Derivatives by Mixed Kernel SVM Enhanced with CLPSO. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40872484 | PubMed |
| 40483538 | J-REGISTER: real-world study of Japanese patients with EGFR mutation-positive NSCLC treated with first-line afatinib. | Future Oncol | 2025 | https://conductscience.org/library/papers/40483538 | PubMed |
| 40410444 | *Mechanisms of circular RNA in drug resistance of lung cancer: therapeutic targets, biomarkers, and future research directions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40410444 | PubMed |
| 40365309 | Ethyl acetate extract of Ruta graveolens: a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40365309 | PubMed |
| 40325239 | Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs. | Med Oncol | 2025 | https://conductscience.org/library/papers/40325239 | PubMed |
| 40280908 | Engineering aptamer-directed phosphatase recruiting chimeras: a strategy for modulating receptor function and overcoming drug resistance. | Nat Commun | 2025 | https://conductscience.org/library/papers/40280908 | PubMed |
| 40259053 | Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1. | Cell Res | 2025 | https://conductscience.org/library/papers/40259053 | PubMed |
| 40255257 | Investigating the anticancer properties of starter culture of Tripura: an in-silico study on non-small cell lung cancer. | In Silico Pharmacol | 2025 | https://conductscience.org/library/papers/40255257 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32014348
GET https://conductscience.org/api/papers/v1/32014348/cited_by?page=2